Search research articles
Contact Us
Filters
Showing results (31-40 of 104) with videos related to
Page
of 11
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 27, 2004
The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis
Shahriar Dabiri, David Huntsman, Nikita Makretsov, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 11, 2021
Association Between Regional Nodal Irradiation and Breast Cancer Recurrence-Free Interval for Patients With Low-Risk, Node-Positive Breast Cancer
Daegan Sit, Nafisha Lalani, Elisa Chan, et al.
BMC Cancer
|
July 11, 2013
Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers
Reka Pataky, Linlea Armstrong, Stephen Chia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2004
Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction
Corinna Warburton, Wieslawa H Dragowska, Karen Gelmon, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
August 28, 2020
Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer
Jolene Guenter, Shirin Abadi, Howard Lim, et al.
Investigational New Drugs
|
September 1, 2005
A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130
Karen A Gelmon, Karl Belanger, Denis Soulieres, et al.
Clinical Breast Cancer
|
October 9, 2007
Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer
Eleni Andreopoulou, Darci Gaiotti, Eugene Kim, et al.
Studies in Health Technology and Informatics
|
February 8, 2013
The development of a standardized software platform to support provincial population-based cancer outcomes units for multiple tumour sites: OaSIS - Outcomes and Surveillance Integration System
Jonn Wu, Cheryl Ho, Janessa Laskin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2009
Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer
Stephen Chia, Susan Dent, Susan Ellard, et al.
The Oncologist
|
March 13, 2020
Effects of High Anxiety Scores on Surgical and Overall Treatment Plan in Patients with Breast Cancer Treated with Neoadjuvant Therapy
Nathalie LeVasseur, Huaqi Li, Winson Cheung, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 104) with videos related to
Sort By:
Page
of 11
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 27, 2004
The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis
Shahriar Dabiri, David Huntsman, Nikita Makretsov, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 11, 2021
Association Between Regional Nodal Irradiation and Breast Cancer Recurrence-Free Interval for Patients With Low-Risk, Node-Positive Breast Cancer
Daegan Sit, Nafisha Lalani, Elisa Chan, et al.
BMC Cancer
|
July 11, 2013
Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers
Reka Pataky, Linlea Armstrong, Stephen Chia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2004
Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction
Corinna Warburton, Wieslawa H Dragowska, Karen Gelmon, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
August 28, 2020
Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer
Jolene Guenter, Shirin Abadi, Howard Lim, et al.
Investigational New Drugs
|
September 1, 2005
A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130
Karen A Gelmon, Karl Belanger, Denis Soulieres, et al.
Clinical Breast Cancer
|
October 9, 2007
Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer
Eleni Andreopoulou, Darci Gaiotti, Eugene Kim, et al.
Studies in Health Technology and Informatics
|
February 8, 2013
The development of a standardized software platform to support provincial population-based cancer outcomes units for multiple tumour sites: OaSIS - Outcomes and Surveillance Integration System
Jonn Wu, Cheryl Ho, Janessa Laskin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2009
Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer
Stephen Chia, Susan Dent, Susan Ellard, et al.
The Oncologist
|
March 13, 2020
Effects of High Anxiety Scores on Surgical and Overall Treatment Plan in Patients with Breast Cancer Treated with Neoadjuvant Therapy
Nathalie LeVasseur, Huaqi Li, Winson Cheung, et al.
Page
of 11